RxDoctor Payments Data

Rachel Wayne, MD

Rheumatology · Little Rock, ARNPI 1780792689

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $661 of the $770 with a category attached, or 85.9%. 9 manufacturers reported payments, led by Amgen at 38.8% of the total. That places this record below the midpoint for rheumatology clinicians in AR, where the typical reported total is $4,419.

$770in general payments, 2019–2025

Across 27 payments — averaging $28.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$299
  • Janssen Scientific Affairs, LLC$129
  • GSK$116
  • Pfizer$95
  • E.r. Squibb & Sons, L.L.C.$71
  • Genentech USA, Inc.$18
  • plus $42 from 3 others

What the payments were for

  • Food & beverage$66186%
  • Education$10914%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$770 in reported general payments places this provider in the 30th percentile of 48 rheumatology providers in Arkansas.

See all rheumatology providers in Arkansas

Medicare billing

Part B allowed, 2024
$710,205
Medicare patients
222
Services billed
42,042

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept70$608,085
XeljanzTofacitinib Citrate61$364,341
Humira(Cf) PenAdalimumab41$292,471
Humira PenAdalimumab18$144,584
RinvoqUpadacitinib13$84,033
Hydroxychloroquine Sulfate429$13,326
Mycophenolate Mofetil20$12,206
MethotrexateMethotrexate Sodium464$7,779
Cevimeline Hcl35$3,139
Sulfasalazine69$1,888
Azathioprine34$1,308
Leflunomide76$1,306
Prednisone156$1,304
Pilocarpine Hcl19$1,242
Celecoxib60$913

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerXeljanz$95$364,34161 claims
AbbVieRinvoq$14$84,03313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 48 rheumatology providers in Arkansas.

Other rheumatology in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →